Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
"Endometriosis, a modern syndrome"
Tiny distinction
Patients taking tirzepatide reached a mean maximum reduction of 14.7% of body weight, or 16.0 kilograms, compared with 10.8%, or 11.6 kilograms, for semaglutide
Finally, we discuss this model with respect to current GLP-1-based therapies and suggest ongoing research in order to maximize the effectiveness of GLP-1-based treatment of obesity
Features could include: Realistic, achievable goal-setting with clear routines for positive habit formation, movement, hydration, nutrition, and mental health Personalized meal & exercise plans tailored to the GLP-1 medication, patients goals, lifestyle, and progress Interventions based on CBT to keep up motivation, help prevent relapses, and avoid emotional eating Integration of data from leading health apps Real-world evidence of patient outcomes In addition to supporting patients in achieving sustainable weight loss, a GLP-1 support app could provide pharma companies with structured, clinically meaningful data on treatment journeys and experience
